BOSTON – From the welcoming remarks to the plenary session and workshops, the message to BioPharm America 2012 attendees was loud and clear: Partnering is all about value creation.

Pfizer Inc. staked its claim in China's growing generics market by joining Zhejiang Hisun Pharmaceutical Co. Ltd. to create Hisun-Pfizer Pharmaceuticals Co. Ltd.

A slew of recent failures in Alzheimer's disease (AD) could prove providential for NeuroNascent Inc., which has ambitious plans to halt and potentially reverse a range of neurodegenerative diseases.

The melancholy on the Geron Corp. conference call early Monday morning was palpable after the company disclosed its decision to halt the Phase II study of imetelstat in metastatic HER2-negative breast cancer after an unplanned interim analysis revealed a greater number of deaths in the treatment arm than the comparator arm.

Newly launched Canadian biotech Fedora Pharmaceuticals Inc. has landed in the antibiotics space with multiple beta-lactamase inhibitor candidates in the lead optimization stage of preclinical development and investigational new drug-enabling studies expected to begin next year.

Privately held Kalidex Pharmaceuticals Inc. is set to debut on the biotech stage with an oral presentation and two dozen posters on its broad-spectrum, next-generation fluoroquinolone, KPI-10, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which begins Sunday in San Francisco.

Intercept Pharmaceuticals Inc. became the third biotech in three weeks to file an S-1 registration statement with the SEC for a proposed initial public offering (IPO), following Regulus Therapeutics Inc. and OvaScience Inc. into the queue.

Australian drug developer CBio Ltd. acquired privately held Inverseon Inc. in an all-stock deal, creating Invion Ltd., which will operate from offices in San Francisco and Brisbane.

Going against the grain, Ceptaris Therapeutics Inc. is seeking to parlay a single asset in a rare form of cancer into both clinical and financial success.